{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T16:06:24.382982+00:00","company":{"ticker":"APYX","cik":719135,"company_name":"Apyx Medical Corp"},"pagination":{"limit":100,"returned":13,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"802b8290608212feec39b5af2068d70387732886","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":"$0.05 per share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to stockholders of $2.1 million","period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"total revenue of $12.5 million"},"claim":"Apyx Medical Corp reported the first quarter ended March 31, 2026 results: revenue total revenue of $12.5 million, net income Net loss attributable to stockholders of $2.1 million, EPS $0.05 per share. Guidance raised.","evidence_excerpt":"99.1) ---\n\nEX-99.1 2 ex_905122.htm EXHIBIT 99.1 ex_905122.htm EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2026 Financial Results •   Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment •   Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-015352","anchor_url":"https://secwatch.observer/filing/0001437749-26-015352#claim-802b8290608212feec39b5af2068d70387732886","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000143774926015352/0001437749-26-015352-index.htm"},{"fact_type":"governance_change","fact_key":"16038182227eb023148fa4be1b9e18a30ba8beda","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2025-12-12T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-08","item_codes_triggered":["5.03"],"summary_text":"Removed Article EIGHTH from Certificate of Incorporation and replaced with 'intentionally omitted'"},"claim":"Apyx Medical Corp: Removed Article EIGHTH from Certificate of Incorporation and replaced with 'intentionally omitted' (effective 2025-12-08).","evidence_excerpt":"On December 8, 2025, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Amendment.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-027481","anchor_url":"https://secwatch.observer/filing/0001493152-25-027481#claim-16038182227eb023148fa4be1b9e18a30ba8beda","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000149315225027481/0001493152-25-027481-index.htm"},{"fact_type":"executive_change","fact_key":"94420162d1","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2025-02-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-28","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Shawn Roman was appointed as Chief Operating Officer at Apyx Medical Corp.","evidence_excerpt":"following the prior announcement that it had appointed Shawn Roman as its Chief Operating Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-25-003036","anchor_url":"https://secwatch.observer/filing/0001437749-25-003036#claim-94420162d1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000143774925003036/0001437749-25-003036-index.htm"},{"fact_type":"executive_change","fact_key":"f435e0e377","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-11-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-06","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Shawn D. Roman was appointed as Chief Operating Officer at Apyx Medical Corp.","evidence_excerpt":"On November 6, 2024, the Board appointed Shawn D. Roman as the Chief Operating Officer of the Company, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-044154","anchor_url":"https://secwatch.observer/filing/0001493152-24-044154#claim-f435e0e377","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000149315224044154/0001493152-24-044154-index.htm"},{"fact_type":"executive_change","fact_key":"f48f6fabe0","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-11-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Craig Swandal resigned as Director at Apyx Medical Corp.","evidence_excerpt":"On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-044154","anchor_url":"https://secwatch.observer/filing/0001493152-24-044154#claim-f48f6fabe0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000149315224044154/0001493152-24-044154-index.htm"},{"fact_type":"executive_change","fact_key":"a1836345f2","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-11-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Geraghty resigned as Director at Apyx Medical Corp.","evidence_excerpt":"On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-044154","anchor_url":"https://secwatch.observer/filing/0001493152-24-044154#claim-a1836345f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000149315224044154/0001493152-24-044154-index.htm"},{"fact_type":"executive_change","fact_key":"ef8a401ff9","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-11-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-04","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"John Andres resigned as Director at Apyx Medical Corp.","evidence_excerpt":"On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-044154","anchor_url":"https://secwatch.observer/filing/0001493152-24-044154#claim-ef8a401ff9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000149315224044154/0001493152-24-044154-index.htm"},{"fact_type":"earnings_release","fact_key":"212253dde1be04d8d05d2074deeb90ba2b45bdfc","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"year ending December 31, 2024","report_date":"2024-05-09","result_type":"guidance_update","revenue_text":"$49.7 million to $52.9 million"},"claim":"Apyx Medical Corp reported year ending December 31, 2024 results: revenue $49.7 million to $52.9 million. Guidance reaffirmed.","evidence_excerpt":"respectively . Full Year 2024 Financial Outlook: The Company is reaffirming its financial guidance for the year ending December 31, 2024: • Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000719135-24-000024","anchor_url":"https://secwatch.observer/filing/0000719135-24-000024#claim-212253dde1be04d8d05d2074deeb90ba2b45bdfc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm"},{"fact_type":"earnings_release","fact_key":"09dc3749e98ec1e898be19da3ad1368d2079fec8","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"eps_text":"$0.22 per share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$7.6 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-09","result_type":"reported_results","revenue_text":"$10.2 million"},"claim":"Apyx Medical Corp reported first quarter ended March 31, 2024 results: revenue $10.2 million, net income $7.6 million, EPS $0.22 per share. Guidance reaffirmed.","evidence_excerpt":"quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024 First Quarter 2024 Financial Summary : • Total revenue of $10.2 million, a decrease of 16% year-over-year. ◦ Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. ◦ OEM revenue of $2.8 million, an increase of 14% year-over-year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000719135-24-000024","anchor_url":"https://secwatch.observer/filing/0000719135-24-000024#claim-09dc3749e98ec1e898be19da3ad1368d2079fec8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm"},{"fact_type":"executive_change","fact_key":"f8a82d1f51","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-07","interim":false,"role":"Director and Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Stavros Vizirgianakis was appointed as Director and Chairman of the Board at Apyx Medical Corp.","evidence_excerpt":"On May 7, 2024, the Board appointed Mr. Vizirgianakis to serve as a director and Chairman of the Board, to fill the vacancy created by the retirement of Andrew Makrides.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000719135-24-000023","anchor_url":"https://secwatch.observer/filing/0000719135-24-000023#claim-f8a82d1f51","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000023/0000719135-24-000023-index.htm"},{"fact_type":"executive_change","fact_key":"4dfdf26021","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-05-09T23:59:59+00:00","payload":{"action":"retired","action_category":"departure","departure_tone":"retirement","effective_date":"2024-05-07","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Stavros Vizirgianakis","successor_named":true},"claim":"Andrew Makrides retired as Chairman of the Board at Apyx Medical Corp.","evidence_excerpt":"On May 7, 2024, Andrew Makrides announced his retirement as a director and Chairman of the Board, effective on the same date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000719135-24-000023","anchor_url":"https://secwatch.observer/filing/0000719135-24-000023#claim-4dfdf26021","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000023/0000719135-24-000023-index.htm"},{"fact_type":"earnings_release","fact_key":"145ccb55557d8ad66199be2f32b3f3c604dcb959","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-03-21T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to stockholders of $18.7 million","period_text":"year ended December 31, 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":"$52.3 million"},"claim":"Apyx Medical Corp reported year ended December 31, 2023 results: revenue $52.3 million, net income Net loss attributable to stockholders of $18.7 million. Guidance initiated.","evidence_excerpt":"or 59%, year-over-year. • Adjusted EBITDA loss of $4.7 million, an increase of $0.6 million, or 14%, year-over-year. Full Year 2023 Financial Summary : • Total revenue of $52.3 million, an increase of 18% year-over-year. ◦ Advanced Energy revenue of $43.4 million, an increase of 18% year-over-year. ◦ OEM revenue of $9.0 million, an increase of 16%","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0000719135-24-000013","anchor_url":"https://secwatch.observer/filing/0000719135-24-000013#claim-145ccb55557d8ad66199be2f32b3f3c604dcb959","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm"},{"fact_type":"earnings_release","fact_key":"5ae2a0635677e943ba1f521322c0a5ac57e976b7","cik":719135,"ticker":"APYX","company_name":"Apyx Medical Corp","filed_at":"2024-03-21T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to stockholders of $9.6 million","period_text":"three months ended December 31, 2023","report_date":"2024-03-21","result_type":"reported_results","revenue_text":"$14.7 million"},"claim":"Apyx Medical Corp reported three months ended December 31, 2023 results: revenue $14.7 million, net income Net loss attributable to stockholders of $9.6 million.","evidence_excerpt":"full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary : • Total revenue of $14.7 million, an increase of 16% year-over-year. ◦ Advanced Energy revenue of $12.1 million, an increase of 15% year-over-year. ◦ OEM revenue of $2.5 million, an increase of 22%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000719135-24-000013","anchor_url":"https://secwatch.observer/filing/0000719135-24-000013#claim-5ae2a0635677e943ba1f521322c0a5ac57e976b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm"}]}